Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Raw Materials (2019 - 2025)

Aytu Biopharma (AYTU) has disclosed Raw Materials for 7 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 144.94% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 144.94% year-over-year, with the annual reading at $1.1 million for FY2025, 319.17% up from the prior year.
  • Raw Materials for Q4 2025 was $1.2 million at Aytu Biopharma, down from $1.4 million in the prior quarter.
  • The five-year high for Raw Materials was $2.6 million in Q3 2021, with the low at $266000.0 in Q2 2024.
  • Average Raw Materials over 5 years is $1.6 million, with a median of $1.8 million recorded in 2022.
  • The sharpest move saw Raw Materials surged 471.54% in 2021, then plummeted 79.55% in 2024.
  • Over 5 years, Raw Materials stood at $2.4 million in 2021, then decreased by 26.41% to $1.8 million in 2022, then decreased by 7.39% to $1.7 million in 2023, then plummeted by 70.13% to $494000.0 in 2024, then skyrocketed by 144.94% to $1.2 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $1.2 million, $1.4 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.